Keith Laderoute, Ph.D.

SRI International
email: keith.laderoute@sri.com

Grants

Novel Anti-Angiogenic Agents for Breast Cancer Therapy 2000 (Cycle VI)
IDEAS II 6JB-0087 $366,022
Novel Anti-vascular Agents for Breast Cancer Therapy 1998 (Cycle IV)
ITaMoCAs 4CB-0032 $353,908


The novel tubulin-binding drug BTO-956 inhibits R3230AC mammary carcinoma growth and angiogenesis in Fischer 344 rats.
  Periodical: Clinical Cancer Research
  Author(s): Shan S, Lockhart AC, Saito WY, Knapp AM, Laderoute KR, Dewhirst MW
  Yr: 2001 Vol: 7 Nbr: 8 Pgs: 2590-96
  Associated Grant: Novel Anti-vascular Agents for Breast Cancer Therapy